Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Public Health

Anthrax: walking the fine line between precaution and panic

Erica Weir
CMAJ November 27, 2001 165 (11) 1528;
Erica Weir
CMAJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Background and epidemiology: With this issue, CMAJ's Public Health page is taking its third look at anthrax in as many years.1,2 With each visit, the essence of the disease, caused by Bacillus anthracis, does not change. Anthrax in Canada remains primarily a disease of herbivores, particularly bison and deer. B. anthracis spores lie dormant in contaminated soil until ingested or inhaled by grazing animals; they germinate in the animals and release toxins that cause massive edema, hemorrhagic lymphadenitis and death from shock. The spores pose little threat unless exceptional circumstances allow transmission by inhalation, inoculation through an open wound or ingestion. Direct person-to-person spread has not been documented. Human cases in Canada have been virtually eliminated thanks to livestock vaccination, industrial sanitary programs, restrictions on imported wool and other products, and proper disposal of infected animals; Canada's last human case, involving dermal exposure, occurred in 1990.3

Since Sept. 11, 2001, exceptional circumstances have arisen in the US because of bioterrorist activity. By Oct. 25, a series of targeted letters, aimed primarily at the media and politicians, had resulted in 3 fatal cases of inhalational anthrax.4 To date, and despite many false alarms, including some outright pranks, there is no evidence of any intentional exposures or active cases of anthrax in Canada. As the prospect of bioterrorism becomes clearer, doctors, patients and public health officials must help each other walk the fine line between precaution and panic.

Clinical management: Inhalational anthrax results from the inspiration of 8000 to 50 000 spores of B. anthracis. The incubation period ranges from 1 to 7 days, but may be up to 60 days. It begins with a brief prodrome that resembles a viral respiratory illness, but rapidly deteriorates to dyspnea and hypoxia, with radiographic evidence of a widened mediastinum. Respiratory failure, shock and meningitis ensue; case-fatality estimates are extremely high despite supportive care and appropriate antibiotic treatment.4 (Intravenous ciprofloxacin is the first-line treatment; doxycycline is an acceptable alternative, although rare doxycycline-resistant strains exist.5)

The skin lesion of cutaneous anthrax evolves from a papule through a vesicular stage, to a depressed black eschar. The incubation period is 1 to 12 days. The lesion is usually painless, but the patient often has fever, malaise, headache and regional lymphadenopathy. The case-fatality rate for cutaneous anthrax is 20% without and less than 1% with antibiotic treatment.4

Gastrointestinal anthrax presents with severe abdominal pain, fever and septicemia. The incubation period is 1 to 7 days after ingesting contaminated meat. Lower bowel inflammation causes nausea, loss of appetite, hematemesis and bloody diarrhea. There is also an oropharyngeal form that is characterized by lesions at the base of the tongue, dysphagia and lymphadenopathy. The case-fatality rate is 25% to 60%, and the effect of early antibiotic treatment is not established.4

Diagnosis is by culture from blood, skin lesions, respiratory secretions or serology; polymerase chain reaction (PCR) testing is available in some laboratories. Early antibiotic treatment can ameliorate the course of anthrax. Postexposure prophylaxis may be achieved in adults, including pregnant and immunocompromised persons, with oral ciprofloxacin (500 mg po bid) or doxycycline (100 mg po bid) for 60 days. Children should receive 10 to 15 mg/kg of ciprofloxacin po q12 hrs for 60 days (not to exceed 1 g per day). Doxycycline is a possible substitute, with doses varying according to the child's age.4

Control and prevention: If a suspicious package is encountered — excessive postage, handwritten addresses, incorrect titles, misspellings of common words, stains or odours, and no return address — do not shake or open it. Cover it and any spillage, leave the room, close the door and section off the room. Wash your hands with soap and water. Phone the police and then make a list of all people present when the letter or package was recognized. Seal contaminated clothing in a plastic bag and take a shower with soap and water as soon as possible.6

Despite those warnings, the risk of anthrax exposure in Canada remains remote. Physicians are reminded that inappropriate use of prophylactic antibiotics leads to increased resistance among micro-organisms and may result in adverse effects such as Clostridium difficile colitis and allergic reactions. Stockpiling antibiotics and purchasing gas masks are discouraged. Anthrax vaccine is currently in short supply and not available to the general public or medical community. It requires 6 injections over 18 months.

Figure

Figure. Photo by: Canapress

References

  1. 1.↵
    Hoey J. Anthrax. CMAJ 1998;158(5):633.
    OpenUrlFREE Full Text
  2. 2.↵
    Weir E. Anthrax: of bison and bioterrorism. CMAJ 2000;163(5):608.
    OpenUrlFREE Full Text
  3. 3.↵
    Wong C, Ng T. Cutaneous anthrax – British Columbia. Can Dis Wkly Rep 1991;17(6):31-3.
    OpenUrlPubMed
  4. 4.↵
    Update: Investigation of anthrax associated with intentional exposure and interim public health guidelines, October 2001. Morb Mortal Wkly Rep 2001;50:889-93.
    OpenUrlPubMed
  5. 5.↵
    Cieslak TJ, Eitzen E. Clinical and epidemiologic principles of anthrax. Emerg Infect Dis 2000;6:1-7. Available: www.cdc.gov/ncidod/EID/vol5no4/cieslak.htm (accessed 2001 Oct 22).
    OpenUrlCrossRefPubMed
  6. 6.↵
    Centers for Disease Control and Prevention. CDC Health Advisory: how to handle anthrax and other biological agent threats. Available: www .states news .org/domestic%20terrorism/CDC _anthrax .htm (accessed 2001 Oct 22).
PreviousNext
Back to top

In this issue

CMAJ
Vol. 165, Issue 11
27 Nov 2001
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Anthrax: walking the fine line between precaution and panic
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Anthrax: walking the fine line between precaution and panic
Erica Weir
CMAJ Nov 2001, 165 (11) 1528;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Anthrax: walking the fine line between precaution and panic
Erica Weir
CMAJ Nov 2001, 165 (11) 1528;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Seasonal drinking: Let's avoid the “January effect”
  • Influenza in children
  • Latent tuberculosis: revised treatment guidelines
Show more Public Health

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire